SPATA17-AS1

Across TCGA pan-cancer cohorts, SPATA17-AS1 RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated SPATA17-AS1 data layer.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher SPATA17-AS1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPATA17-AS1 expression acts as an unfavorable survival marker, although some lineages such as BRCA and SKCM show a favorable association.

READ, UCEC, and LUSC are the cancer types where SPATA17-AS1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	DFS	Tertile	II,III,IV	0.183	0.551	<.001	99	view →
UCEC	DFS	Tertile	III,IV	0.339	0.635	.017	42	view →
LUSC	OS	Tertile	IV	0.001	0.673	.014	39	view →
BRCA	DFS	Median	III,IV	0.936	0.831	<.001	37	view →
MESO	OS	Tertile	III,IV	0.395	0.589	.029	36	view →
DLBC	OS	Tertile	II,III,IV	0.534	0.917	.004	36	view →
KICH	OS	Tertile	All	0.155	0.926	<.001	27	view →
SKCM	DFS	Tertile	All	0.328	0.186	.010	27	view →
THCA	DFS	Tertile	II,III,IV	0.501	0.738	.020	24	view →
SARC	OS	Tertile	All	0.166	0.509	.008	18	view →
COAD	OS	Tertile	All	0.374	0.721	.012	9	view →
CHOL	DFS	Tertile	III,IV	0.133	0.779	.038	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

SPATA17-AS1–READ (DFS)

Open the READ breakdown →